$Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan$

Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan

BackgroundThe therapeutic options of relapsed or refractory multiple myeloma (RRMM) remain a challenge. The MM-003 trial demonstrated that RRMM patients treated with pomalidomide and dexamethasone (Pom/Dex) have better progression-free survival (PFS) than those treated with high-dose dexamethasone a...

Full description

Bibliographic Details
Main Authors:	Yu-Chin Hung, Jyh-Pyng Gau, Shang-Yi Huang, Bor-Sheng Ko, Chieh-Lin Jerry Teng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-05-01
Series:	Frontiers in Oncology
Subjects:	multiple myeloma pomalidomide treatment response refractory relapse
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.695410/full

Similar Items

Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Single-Centre Study, Real-Life Experience
by: İbrahim Halil Açar, et al.
Published: (2023-08-01)

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
by: Arleigh McCurdy, et al.
Published: (2022-03-01)

Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01)

Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial
by: Wei-Jun Fu, et al.
Published: (2022-07-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)

Pomalidomide for the management of relapsed and refractory multiple myeloma: a case report and review of literature
by: S. V. Semochkin
Published: (2015-10-01)

PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
by: M. Yu. Frolov, et al.
Published: (2017-08-01)

Pomalidomide in the management of relapsed/refractory multiple myeloma: A review
by: Sergej Semochkin
Published: (2023-08-01)

Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relapsed/Refractory Multiple Myeloma
by: Omar Nadeem, et al.
Published: (2024-02-01)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
by: Xiang Zhou, et al.
Published: (2020-08-01)

Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World “POWERFUL” Study
by: Evangelos Terpos, et al.
Published: (2021-04-01)

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
by: Rios-Tamayo R, et al.
Published: (2017-08-01)

The role of pomalidomide in treatment of relapse and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2022-01-01)

Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary
by: Szilvia Lovas, et al.
Published: (2022-10-01)

Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival
by: Rao Prabhala, et al.
Published: (2023-12-01)

Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series
by: Faouzi Djebbari, et al.
Published: (2022-12-01)

Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
by: Maria Livia Del Giudice, et al.
Published: (2021-08-01)

Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study
by: Faouzi Djebbari, et al.
Published: (2022-12-01)

Pomalidomide-based therapy for extramedullary multiple myeloma
by: Yating Li, et al.
Published: (2022-12-01)

How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
by: Francesca Fazio, et al.
Published: (2022-02-01)

Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael M, et al.
Published: (2010-01-01)

Treatment of double-refractory multiple myeloma
by: S. V. Semochkin
Published: (2021-09-01)

Multi-omics investigation of the resistance mechanisms of pomalidomide in multiple myeloma
by: Yan Zhuang, et al.
Published: (2023-09-01)

Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)
by: Ga-Young Song, et al.
Published: (2023-10-01)

Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study
by: Tran-Der Tan, et al.
Published: (2020-01-01)

Pomalidomide induced lupus type hypersensitivity reaction
by: Chinmay Jani, et al.
Published: (2021-03-01)

Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model
by: Manh-Cuong Vo, et al.
Published: (2018-08-01)

The Role of Pomalidomide-Based Epigenetic Effect on DNMT Genes Expression in Myeloma Cell Line
by: Ali Dehghani Fard, et al.
Published: (2018-06-01)

Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe
by: Evangelos Terpos, et al.
Published: (2022-10-01)

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function
by: Li Y, et al.
Published: (2017-11-01)

Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review
by: Tung-Lung Yang, et al.
Published: (2023-11-01)

Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors
by: Fevzi Fırat Yalnız, et al.
Published: (2017-08-01)

Long-Term Disease Control by Pomalidomide-/Dexamethasone-Based Therapy in a Patient with Advanced Multiple Myeloma: A Case Report and Review of the Literature
by: Sophia Danhof, et al.
Published: (2015-04-01)

Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
by: Maral DerSarkissian, et al.
Published: (2023-12-01)

Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
by: Vera A. Zherebtsova, et al.
Published: (2021-07-01)

Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review
by: Aneta Szudy-Szczyrek, et al.
Published: (2021-06-01)

The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma
by: Mark Sellin, et al.
Published: (2022-08-01)

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
by: Joseph NS, et al.
Published: (2021-08-01)